SONY

Product Data Sheet

Brilliant Violet 421™ anti-human CD158e1 (KIR3DL1, NKB1)

Catalog # / Size: 2163565 / 25 tests
2163570 / 100 tests

Clone: DX9

Isotype: Mouse IgG1, κ

Immunogen: Human NK cell clone VL186-1.6

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD56 APC and CD158e1 (clone DX9) Brilliant Violet 421™ (top) or mouse IgG1 Brilliant Violet 421™ isotype control (bottom).



Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

Application Notes: The DX9 antibody reacts with the KIR (killer cell inhibitory receptor) designated NKB1 or KIR3DL1. Additional reported applications (for the relevant formats) include: immunoprecipitation1 and restoring the NK cell cytotoxicity[4,8]. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 312710).

Application References:

1. Litwin V, *et al.* 1994. *J. Exp. Med.* 180:537. (IP)
2. Gumperz J, *et al.* 1996. *J. Exp. Med.* 183:1817.
3. Gardiner CM, *et al.* 2001. *J. Immunol.* 166:2992.
4. Bakker ABH, *et al.* 1998. *J. Immunol.* 160:5239.
5. Goodier M, *et al.* 2000. *J. Immunol.* 165:139.
6. Kirwan SE and Burshtyn DN. 2005. *J. Immunol.* 175:5006. (FC)
7. Yawata M, *et al.* 2002. *Immunogenetics* 54:543.
8. Valiante NM, *et al.* 1997. *Immunity* 7:739.
9. Pascal V, *et al.* 2007. *J. Immunol.* 179:1625. (FC) PubMed
10. Lichterfeld M, *et al.* 2008. *J. Exp. Med.* 204:2813. (FC) PubMed
11. Terszowski G, *et al.* 2014. *J Immunol.* 192:5618. PubMed
12. Boudreau JE, *et al.* 2014. *PLoS One.* 9:99543. PubMed
13. Purdy AK, *et al.* 2014. *J Immunol.* 193:4675. PubMed
14. Lisovsky I, *et al.* 2015. *J Lukoc Biol.* 97:761. PubMed

---

Description: CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.

Antigen References:

1. Colonna M, *et al.* 1995. *Science* 268:405.
2. D'Andrea A, *et al.* 1995. *J. Immunol.*. 155:2306.
3. Uhrburg M, *et al.* 1997. *Immunity* 7:753.
4. Gumperz JE, *et al.* 1996. *J. E*